Milestone Pharmaceuticals (NASDAQ:MIST) Downgraded to “Sell” Rating by Wall Street Zen

Wall Street Zen cut shares of Milestone Pharmaceuticals (NASDAQ:MIST) from a hold rating to a sell rating in a research note released on Saturday.

A number of other equities research analysts also recently issued reports on the company. TD Cowen upgraded Milestone Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.00 price objective on the stock in a research report on Monday, December 15th. HC Wainwright reissued a “buy” rating and set a $8.00 target price on shares of Milestone Pharmaceuticals in a research report on Tuesday, January 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a research report on Monday, December 29th. Wells Fargo & Company lifted their price objective on shares of Milestone Pharmaceuticals from $4.00 to $8.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 16th. Finally, Cowen raised shares of Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, December 15th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.00.

Milestone Pharmaceuticals Price Performance

MIST stock opened at $2.04 on Friday. Milestone Pharmaceuticals has a 52 week low of $0.63 and a 52 week high of $3.06. The firm has a market capitalization of $173.75 million, a P/E ratio of -2.49 and a beta of 0.44. The company has a fifty day simple moving average of $2.23 and a two-hundred day simple moving average of $1.96. The company has a quick ratio of 8.24, a current ratio of 8.24 and a debt-to-equity ratio of 2.74.

Milestone Pharmaceuticals (NASDAQ:MIST) last posted its earnings results on Wednesday, November 12th. The company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.05. Analysts anticipate that Milestone Pharmaceuticals will post -0.62 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Milestone Pharmaceuticals news, CEO Joseph Oliveto sold 43,000 shares of the stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $2.25, for a total value of $96,750.00. Following the sale, the chief executive officer owned 303,721 shares in the company, valued at $683,372.25. This trade represents a 12.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 19.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Sapient Capital LLC bought a new position in Milestone Pharmaceuticals in the 3rd quarter worth about $25,000. Bay Rivers Group purchased a new stake in shares of Milestone Pharmaceuticals in the second quarter valued at approximately $28,000. Bank of America Corp DE grew its stake in Milestone Pharmaceuticals by 200,550.0% in the third quarter. Bank of America Corp DE now owns 16,052 shares of the company’s stock worth $32,000 after purchasing an additional 16,044 shares in the last quarter. Stephenson & Company Inc. bought a new position in Milestone Pharmaceuticals in the third quarter worth approximately $40,000. Finally, Creative Planning increased its holdings in Milestone Pharmaceuticals by 74.6% during the 2nd quarter. Creative Planning now owns 23,410 shares of the company’s stock worth $45,000 after purchasing an additional 10,000 shares during the period. 86.18% of the stock is currently owned by institutional investors.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.